Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castrationresistant prostate cancer: Results from PREVAIL

Julie Graff, G. Baciarello, A. J. Armstrong, C. S. Higano, P. Iversen, T. W. Flaig, D. Forer, T. Parli, D. Phung, B. Tombal, Tomasz (Tom) Beer, C. N. Sternberg

Research output: Contribution to journalArticle

45 Scopus citations

Abstract

Background: Prostate cancer disproportionately affects older men. Because age affects treatment decisions, it is important to understand the efficacy and tolerability of therapies for advanced prostate cancer in elderly men. This analysis describes efficacy and safety outcomes in men aged ≥75 years who received enzalutamide, an androgen receptor inhibitor, in the phase III PREVAIL trial. Patients and methods: PREVAIL was a randomised, double-blind, multinational study of oral enzalutamide 160 mg/day (N = 872) versus placebo (N = 845) in chemotherapy-naive men with metastatic castration-resistant prostate cancer. Overall survival (OS) and radiographic progression-free survival (rPFS) were coprimary end points. Subgroup analysis of men aged ≥75 years (elderly) and men aged

Original languageEnglish (US)
Article numbermdv542
Pages (from-to)286-294
Number of pages9
JournalAnnals of Oncology
Volume27
Issue number2
DOIs
StatePublished - Feb 1 2016

    Fingerprint

Keywords

  • Elderly patients
  • Enzalutamide
  • Metastatic castration-resistant prostate cancer
  • PREVAIL trial

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Graff, J., Baciarello, G., Armstrong, A. J., Higano, C. S., Iversen, P., Flaig, T. W., Forer, D., Parli, T., Phung, D., Tombal, B., Beer, T. T., & Sternberg, C. N. (2016). Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castrationresistant prostate cancer: Results from PREVAIL. Annals of Oncology, 27(2), 286-294. [mdv542]. https://doi.org/10.1093/annonc/mdv542